VIDEO: ‘Real-world’ findings on epcoritamab, glofitamab in large B-cell lymphoma
SAN DIEGO — Paolo Caimi, MD, spoke with Healio about results from the REALBiTE study presented at Annual Meeting and Exposition.
The retrospective multicenter cohort study investigated heavily pretreated patients with relapsed or refractory large B-cell lymphoma who had received epcoritamab (Epkinly; Genmab, AbbVie) or glofitamab (Columvi, Genentech).
Caimi, a physician and clinical investigator at Cleveland Clinic, said that the researchers found the “real-world performance of these drugs is a little bit worse than what you would see in clinical trials, which is normal and to be expected as patients are more heavily pretreated — particularly when drugs are just recently approved.”
He added that “it’s still important that they found that there are patients that have excellent responses — that have had sustained responses — though it seems to be a smaller number when the people are heavily pretreated.”
Reference:
Brooks TR, et al. Abstract 111. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
Collapse
Healio Interviews
Read more about